Enterprise Value
8.255B
Cash
2.863B
Avg Qtr Burn
N/A
Short % of Float
3.24%
Insider Ownership
1.76%
Institutional Own.
98.93%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Remunity™ (treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Approved Quarterly sales | |
Tyvaso (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Tyvaso DPI™ (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3 | Approved Quarterly sales | |
Tyvaso (inhaled treprostinil) Details Pulmonary fibrosis, Idiopathic pulmonary fibrosis | Phase 3 Data readout | |
Ralinepag (IP receptor agonist) Details Pulmonary hypertension | Phase 3 Data readout | |
Tyvaso (inhaled treprostinil) Details Pulmonary hypertension, Chronic obstructive pulmonary disease | Phase 3 Update | |
Trevyent® (treprostinil sodium) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH) | Failed Discontinued |